{"name":"Genelabs Technologies","slug":"genelabs-technologies","ticker":"","exchange":"","domain":"","description":"Genelabs Technologies is a biotechnology company focused on the development of innovative therapies in various therapeutic areas. The company has a pipeline of three drugs, with two in Phase 3 and one in Phase 2, demonstrating its commitment to advancing treatments for unmet medical needs.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Trichosanthin","genericName":"Trichosanthin","slug":"trichosanthin","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Trichosanthin","genericName":"Trichosanthin","slug":"trichosanthin","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNVkJtX1ZRNFEyOXFibm1ZUGdhRUluS3dyaDdwMkxiUzJCV1dMM19WZlozU1pPU1h5d2IxZXY4dUkxOTBsR0c4SGs3WklEamxXbjVWdUhJU051TFZleFc5cEw1N0JOdmdmamE1QVVHNkdyanRER3lUOEhLOTFXXzExZkU3Z1pwUE1FQmlXMTdsTkhmT2RHcjY5RzRRRFUyQkgt?oc=5","date":"2021-05-24","type":"patent","source":"Corrs Chambers Westgarth","summary":"Compulsory patent licences in Australia: time to take another look? - Corrs Chambers Westgarth","headline":"Compulsory patent licences in Australia: time to take another look?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE52MlBkNFN1enF0clpUMnZvTjlrMEdpa2U3RVFZUGk2NlNkTGJjMWJZaDZISmM2UnBHQXZWWW9pZXN3TTh0NzJMVko3MjJ2NUU0RWh5Tk93?oc=5","date":"2018-05-29","type":"pipeline","source":"Nature","summary":"People - Nature","headline":"People","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE1NRE03N2Q3TFpNZ041Zno4bXA0VVZId0xhVVVMQXFPZ0pyN1gtc2NSLVNxelAtbURRMG11RGhFUS0xS0g5S3ZCYXU0U0M5QmNPdnZzN2Q0M3RIZmh3bWdQZHptcjhDS21DYy1LS091VjdMWmpF?oc=5","date":"2010-09-27","type":"pipeline","source":"C&EN","summary":"Leaping To New Opportunities - C&EN","headline":"Leaping To New Opportunities - C&EN","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE44ZlVBRkRPcnFiWGN1SlozWm54ZDdPVXRyYlF3S21LQVhYa2hGR3ZhdVJwT282WVE3U3BHNEVkNGNYUWVicUVDbFprM0c1Wkk4d01zQV8xa3IxYWFjRnlmQklUUHZSUk0?oc=5","date":"2009-07-20","type":"trial","source":"The New York Times","summary":"Trial for New Lupus Treatment Is Called Promising (Published 2009) - The New York Times","headline":"Trial for New Lupus Treatment Is Called Promising (Published 2009)","sentiment":"neutral"},{"date":"2009-02-12","type":"earnings","source":"SEC EDGAR","summary":"SC 13G filed with SEC: SCHEDULE 13G","headline":"SC 13G Filing","sentiment":"neutral"},{"date":"2009-01-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":null,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":null,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}